Steve K. Barbarick - 09 Sep 2021 Form 4 Insider Report for Statera Biopharma, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2021, 16:05:41 UTC
Prior SEC filing: 29 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Peter Aronstam, Attorney-in-fact for Steve K. Barbarick

Filing notes and source

Key filing fact

Steve K. Barbarick filed Form 4 for Statera Biopharma, Inc. on 19 Oct 2021.

Key facts

This page summarizes Steve K. Barbarick's Form 4 filing for Statera Biopharma, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Oct 2021, 16:05.

Change

Previous filing in this sequence was filed on 29 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STAB transaction

Common Stock, par value $0.005 per share

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 09 Sep 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These securities are restricted stock units (RSUs) that were granted pursuant to the Cleveland Biolabs, Inc. Equity Incentive Plan. The RSUs will be settled solely with Issuer Common Stock and vest in equal monthly portions over the period of 36 months from the grant date, provided that the Reporting Person continues to provide services to the Issuer through each vesting date.